The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.

Bernstein SocGen Group reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY) stock Monday, citing continued strong performance of its weight loss medication Zepbound.

UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

(Reuters) -Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical ...

Economists around the world are expecting muted U.S. economic growth in coming quarters, and some indicators suggest a mild recession is a possibility. It may become difficult for investors to ...